SGLT2 inhibitors are diabetes drugs that also protect the heart and kidneys, and that protection is the reason the class is now widely prescribed, beyond its modest effect on blood sugar. They block a transporter in the kidney called SGLT2, so 50 to 80 grams of glucose a day leave in the urine instead of returning to the blood. The effect on blood sugar is modest.
What is large and repeated in trials is the protection of the heart and kidneys: across the class, the most consistent benefits are keeping people with heart failure out of the hospital and slowing chronic kidney disease, and several of those benefits hold in people who do not have diabetes. The cut in cardiovascular death was significant when the trials were pooled but varied between them, so it is not a uniform class effect. The longevity interest is separate and much thinner: canagliflozin extended median lifespan in male but not female mice in one careful animal program, and no completed human trial tests these drugs for healthy aging.
They also carry safety trade-offs:
- ketoacidosis that can happen while blood sugar reads close to normal
- genital yeast infections
- volume depletion
- rare but serious infection of the perineum
There is no dose here, because starting one is a decision made with a clinician.
Findings & Outcomes
What It Is
SGLT2 inhibitors are oral diabetes drugs whose names end the same way: empagliflozin, dapagliflozin and canagliflozin are the main three, sold as Jardiance, Farxiga and Invokana. The letters stand for sodium-glucose cotransporter 2, a protein in the kidney that normally reabsorbs filtered glucose back into the blood. These drugs block it, so glucose that would have been reclaimed leaves in the urine. That is the whole mechanism, and the rest follows from it.
They arrived as a modest way to lower blood sugar. A series of large outcome trials changed that, showing they keep people with heart failure out of the hospital and slow the decline of failing kidneys, with several of those benefits appearing in people who did not have diabetes. Cardiologists and kidney specialists now prescribe them for that protection, often more than for the blood sugar effect that got them approved.
What It Does
The evidence for these drugs comes in two kinds, and they are far apart in strength.
The strong kind is the cardiorenal evidence, from large randomized trials, so it is cause and effect: EMPA-REG OUTCOME, DAPA-HF, DAPA-CKD and CREDENCE. EMPA-REG was the result that changed the standing of the class. Empagliflozin had been approved as a modest glucose drug and was being tested only to prove it did not harm the heart; instead it lowered cardiovascular death by 38% and all-cause death by 32% in people with type 2 diabetes and established heart disease. Across the whole class, the benefits that repeat most reliably are keeping people with heart failure out of the hospital and slowing chronic kidney disease, and for those two the benefit held whether or not the person had diabetes. Death from cardiovascular causes fell significantly in the pooled trials but varied from trial to trial, so unlike the heart-failure and kidney results it is not a uniform class effect.
These pivotal trials were funded by the drugs' makers: EMPA-REG OUTCOME by Boehringer Ingelheim and Eli Lilly, DAPA-HF and DAPA-CKD by AstraZeneca, and CREDENCE and CANVAS by Janssen. That does not overturn the findings, which repeat across separate drugs, companies and independent analyses, but it is a fact to weigh, since manufacturer-funded trials tend to report effects at the favorable edge.
The thin kind is the longevity evidence. It is a single animal result: canagliflozin extended lifespan in male mice, with nothing measurable in females, and no completed human trial has tested any of these drugs for slowing aging in a healthy person. Someone healthy taking one off-label to live longer is acting on that one result, and taking on the safety trade-offs without the disease that justifies them.
The findings below are ordered by the strength of their own evidence: the cardiorenal trials at the top, the modest glucose effect and the mechanism in the middle, the longevity signal near the preliminary end, and the safety signals grouped after them.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Heart And Vascular
Empagliflozin cut cardiovascular death 38% and all-cause death 32% (EMPA-REG)
In people with type 2 diabetes who already had heart disease, empagliflozin lowered the rate of dying from heart causes by nearly two-fifths and cut heart-failure hospital stays by about a third.
In EMPA-REG OUTCOME, empagliflozin reduced cardiovascular death by 38% (HR 0.62), all-cause death by 32% (HR 0.68) and hospitalization for heart failure by 35% (HR 0.65) over a median 3.1 years in adults with type 2 diabetes and established cardiovascular disease. Measured in: 7,020 adults with type 2 diabetes and established cardiovascular disease, mean age 63, about 71% men, median follow-up 3.1 years.. The trial enrolled people who already had cardiovascular disease, so it shows benefit in that higher-risk group rather than in the general population, and participants were about 71% men.
Who this may not transfer to:Trial population was people with type 2 diabetes and established heart disease, about 71% men, so the benefit is shown in that higher-risk group.
The study · 1
Zinman et al., empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME) · N Engl J Med 2015;373:2117-2128
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Dapagliflozin cut worsening heart failure or cardiovascular death 26%, with or without diabetes (DAPA-HF)
In people with a weak heart, dapagliflozin lowered the rate of heart failure getting worse or of dying from heart causes by about a quarter, and it worked just as well in those who did not have diabetes.
In DAPA-HF, dapagliflozin reduced the primary composite of worsening heart failure or cardiovascular death by 26% (HR 0.74) over a median 18.2 months in people with heart failure and reduced ejection fraction, and the benefit was consistent whether or not they had type 2 diabetes. Measured in: 4,744 adults with heart failure and reduced ejection fraction, about 42% with type 2 diabetes, about 77% men, median follow-up 18.2 months.. The trial studied heart failure with reduced ejection fraction specifically, and participants were about 77% men, so the sex balance is skewed.
Who this may not transfer to:Heart failure with reduced ejection fraction, about 77% men; the benefit held with and without diabetes.
The study · 1
McMurray et al., dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF) · N Engl J Med 2019;381:1995-2008
The whole class lowers heart attacks, heart-failure hospitalization and kidney decline (pooled trials)
Pooling the big trials, the whole class reliably lowers heart attacks and strokes, heart-failure hospital stays, and kidney decline, so this is a property of the class and not of a single drug.
A meta-analysis of six large SGLT2 inhibitor outcome trials in type 2 diabetes (46,969 patients) found the class reduced major adverse cardiovascular events, hospitalization for heart failure and kidney disease progression, with the heart-failure and kidney benefits the most consistent across the drugs; the reduction in cardiovascular death was significant overall but varied between the trials. Measured in: Pooled participants from large cardiovascular and renal outcome trials of SGLT2 inhibitors in type 2 diabetes.. The pooled trials enrolled people with type 2 diabetes at elevated cardiovascular or kidney risk, so the class effect is established in that population rather than in low-risk or non-diabetic general populations.
Who this may not transfer to:Pooled from diabetes outcome trials at elevated cardiovascular or kidney risk; not tested in low-risk or non-diabetic general populations.
The study · 1
McGuire et al., association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis · JAMA Cardiol 2021;6:148-158
Kidney Disease
Dapagliflozin cut kidney-disease progression and related death 39% (DAPA-CKD)
In people with chronic kidney disease, dapagliflozin slowed the loss of kidney function and cut the risk of kidney failure by about two-fifths, and it helped those without diabetes too.
In DAPA-CKD, dapagliflozin reduced the primary composite of a sustained fall in kidney function, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61) in people with chronic kidney disease, with benefit whether or not they had type 2 diabetes. Measured in: 4,304 adults with chronic kidney disease, about 67% with type 2 diabetes, about 67% men, trial stopped early for benefit.. The trial was stopped early for clear benefit, which can modestly overstate effect size, and participants were about 67% men.
Who this may not transfer to:Chronic kidney disease, about 67% men; the benefit held with and without diabetes.
The study · 1
Heerspink et al., dapagliflozin in patients with chronic kidney disease (DAPA-CKD) · N Engl J Med 2020;383:1436-1446
Canagliflozin cut kidney failure and related death 30% in diabetic nephropathy (CREDENCE)
In people with diabetes whose kidneys were already spilling protein, canagliflozin cut the risk of kidney failure and related death by about a third.
In CREDENCE, canagliflozin reduced the primary composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death by 30% (HR 0.70) in people with type 2 diabetes and albuminuric chronic kidney disease. Measured in: 4,401 adults with type 2 diabetes and albuminuric chronic kidney disease, about 66% men, trial stopped early for benefit.. This trial was in people with diabetes and existing kidney damage, so it establishes benefit in that population, and it was stopped early for efficacy.
Who this may not transfer to:People with type 2 diabetes and albuminuric kidney disease, about 66% men.
The study · 1
Perkovic et al., canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE) · N Engl J Med 2019;380:2295-2306
How it works
Blocking SGLT2 in the kidney spills 50 to 80 grams of glucose a day into the urine
These drugs stop the kidney from reclaiming glucose, so instead of returning to the blood it leaves in the urine, which lowers blood sugar without needing more insulin.
SGLT2 inhibitors block the sodium-glucose cotransporter 2 in the proximal tubule of the kidney, which normally reabsorbs about 90% of filtered glucose. Blocking it causes roughly 50 to 80 grams of glucose per day to be excreted in the urine, lowering blood sugar independently of insulin, with mild osmotic diuresis and small reductions in weight and blood pressure. The blood-sugar lowering is modest and does not account for the size of the heart and kidney benefits, which are thought to come from fluid unloading, reduced pressure in the kidney filter, and a shift toward ketone metabolism.
Who this may not transfer to:Mechanism of the drug class; applies to anyone taking one.
The study · 1
Peters et al., euglycemic diabetic ketoacidosis: a potential complication of treatment with SGLT2 inhibition · Diabetes Care 2015;38:1687-1693
Blood Sugar
Empagliflozin lowered HbA1c only about 0.3 to 0.5 points, a modest glucose effect
The drop in long-term blood sugar these drugs produce is small, smaller than what metformin or a GLP-1 drug delivers, and it does not explain the heart and kidney gains.
In EMPA-REG OUTCOME, empagliflozin lowered HbA1c by roughly 0.3 to 0.5 percentage points more than placebo over the trial, alongside small reductions in body weight and blood pressure, a modest glucose effect compared with the size of the cardiovascular benefit. Measured in: 7,020 adults with type 2 diabetes and established cardiovascular disease, mean age 63, about 71% men.. This is the between-group HbA1c difference in a cardiovascular outcome trial where background diabetes treatment was adjusted, so it reflects the modest add-on glucose effect rather than a head-to-head glucose-lowering comparison.
Who this may not transfer to:Add-on glucose effect measured in a diabetes cardiovascular trial, about 71% men.
The study · 1
Zinman et al., empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME) · N Engl J Med 2015;373:2117-2128
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Longevity And Mortality
Canagliflozin extended male-mouse median lifespan about 14%, with no effect in females
In a careful animal study, a canagliflozin diet let male mice live about 14% longer on average, while female mice got no benefit.
In the Interventions Testing Program, a rigorous multi-site study in genetically heterogeneous mice, canagliflozin extended median lifespan in males by about 14% but had no significant effect on female lifespan. This is a rodent result and the benefit appeared only in males, so it does not establish any effect on human lifespan and does not transfer to women even at the animal level.
Who this may not transfer to:Rodent result in male mice only; it does not transfer to humans, or to females even at the animal level.
The study · 1
Miller et al., canagliflozin extends life span in genetically heterogeneous male but not female mice · JCI Insight 2020;5:e140019
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
No completed human trial shows these drugs extend healthy lifespan
There is no human trial showing these drugs help healthy people live longer; the proven human benefits are for people who already have heart, kidney or blood sugar disease.
No completed randomized trial tests an SGLT2 inhibitor for extending healthy lifespan or healthspan in people. The human evidence establishes reductions in cardiovascular and kidney disease outcomes in people who already have those conditions, not lifespan extension in healthy adults. The longevity interest rests on a single animal lifespan result in male mice and on mechanism, with no human outcome data for a healthy-aging use.
Who this may not transfer to:No human outcome data for a healthy-aging use; the proven human benefits are in people who already have heart, kidney or blood sugar disease.
The study · 1
Miller et al., canagliflozin extends life span in genetically heterogeneous male but not female mice · JCI Insight 2020;5:e140019
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
How It Works
Anatomy
1What SGLT2 does, and what blocking it means
The kidney filters a large amount of glucose out of the blood every day and normally reabsorbs almost all of it through a transporter called SGLT2 in the proximal tubule. These drugs block that transporter, so instead of being reclaimed, roughly 50 to 80 grams of glucose per day leaves in the urine. That urinary glucose loss lowers blood sugar modestly, pulls a little water and sodium out with it, and produces small drops in weight and blood pressure.
2Why the heart and kidney benefits are larger than the glucose effect
The glucose effect is modest, so it does not explain the heart and kidney results. The leading ideas are that the mild fluid loss unloads a strained heart, that reducing pressure inside the kidney filter protects it over time, and that a shift toward burning ketones may give the heart a more efficient fuel. Which of these matters most is still being worked out, but the outcome data themselves are large and consistent.
3The longevity question
The Interventions Testing Program, a rigorous multi-site animal aging study, found canagliflozin extended median lifespan in male mice by about 14% and did nothing measurable in females. The proposed reasons include the daily loss of glucose calories acting as a mild caloric restriction, and a metabolic switch toward ketones. No completed human trial tests any of these drugs for healthy aging, so this remains a hypothesis grounded in one animal result.
The kidney filters roughly 180 grams of glucose a day and in a healthy person reabsorbs nearly all of it. About 90% of that reabsorption runs through SGLT2, so blocking it lets 50 to 80 grams a day leave in the urine, which lowers blood sugar without requiring the pancreas to make more insulin. For the metabolic system these drugs act on, see insulin and glucose handling; for where metabolic pathways sit among the drivers of aging, see the biology of aging.
If you take one of these drugs, agree a sick-day rule with a prescriber in advance: pause it during serious illness, dehydration, or before surgery, when ketoacidosis is most likely even with near-normal blood sugar.
How to Approach It
This is educational. There are no doses or product links here, because these are prescription drugs and whether one fits is a decision made with a clinician. Below is where the evidence is strongest, and what to weigh before the longevity idea comes up.
The foundations of metabolic and cardiovascular health are exercise, whole foods, sleep and keeping muscle, and no drug substitutes for them. See [resistance training](/go/integrative/practice/resistance-training) for holding muscle with age and [sleep environment](/go/integrative/practice/sleep-environment) for the rest of the foundation.
For heart failure, chronic kidney disease and type 2 diabetes, SGLT2 inhibitors have large trials behind them, including benefits in people without diabetes. Whether one fits your kidney function, blood pressure and other medicines is a conversation with a prescriber, who sets the dose and monitors the response.
Ketoacidosis can happen at near-normal blood sugar with these drugs, so ask a prescriber to set a sick-day rule in advance: pause the drug during serious illness, dehydration, or before surgery. Genital yeast infections are common early, and staying well hydrated matters, especially alongside other diuretics.
For a healthy person without heart, kidney or blood sugar disease, taking one of these to slow aging runs ahead of the evidence, which so far is a single animal result in male mice. There is no completed human trial and no established dose for that use. The reasonable step is to follow the research and weigh it with a clinician.
Go Deeper
- The biology of aging: how a lifespan result in mice should be read against the absence of a human trial, and where metabolic pathways sit among the drivers of aging.
- Insulin and glucose handling: the metabolic system these drugs act on, and why lowering blood sugar through the kidney is different from the other diabetes drugs.
- Metformin: the other cheap diabetes drug at the center of the longevity conversation, with the same gap between animal signal and human proof.
- GLP-1 Medications: the metabolic drug class with the largest weight and cardiovascular effects, often discussed alongside these.
The Chinese Medicine View
SGLT2 inhibitors are products of modern chemistry, developed in the last two decades, so there is no classical Chinese entry for them. No historical text assigns any of them a channel, a temperature or a flavor, and no traditional formula contains one. What follows places them against the tradition as a lens, not as evidence, and borrows no classical claim, because none exists. Nothing here suggests any herb or formula reproduces what these drugs do.
This maps onto a pattern the tradition has described for a long time. Classical Chinese medicine describes Xiao Ke, a wasting-and-thirsting disorder that maps loosely onto what we now call diabetes, and it reads the heavy urination and thirst of that pattern as a sign of Yin depletion with Heat, a condition to resolve. Here the tradition would raise a caution. These drugs work by deliberately increasing the loss of a refined substance, glucose, through the urine, and by pulling fluid out with it. A framework that places a high value on preserving fluids and Yin would count inducing that loss in someone already dry, thirsty or fluid-depleted as the wrong direction, and the dehydration and volume-depletion risk the drugs carry lines up with that concern.
So the tradition would not read deliberate glucose loss as strengthening anything. It would treat these drugs as acting on the downstream picture, the high blood sugar and the strained heart and kidney, while its own aim, a body that transforms and holds its fluids well on its own, stays separate work. This relates a modern class to a framework the tradition has long used; it is not a claim that Chinese medicine explains or endorses these drugs. The evidence for them rests on their own trials, which for heart and kidney disease are large and repeated.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Genital yeast infections rise in both men and women, most often early on
In the CANVAS program, canagliflozin increased genital mycotic infections in both women and men compared with placebo, a consistent effect of putting glucose into the urine and seen across the drug class. Rates come from a diabetes population, and genital infections were common but generally treatable rather than severe.Neal et al., canagliflozin and cardiovascular and renal events in type 2 diabetes (CANVAS Program)
Ketoacidosis can strike while blood glucose reads close to normal, which makes it easy to miss
A case series described diabetic ketoacidosis occurring during SGLT2 inhibitor treatment while blood glucose read close to normal rather than markedly elevated, so-called euglycemic ketoacidosis, precipitated by surgery, acute illness, dehydration, insulin reduction and low-carbohydrate intake. This is a small case series rather than a rate from a controlled trial, so it establishes that the event happens and its triggers rather than a precise incidence.Peters et al., euglycemic diabetic ketoacidosis: a potential complication of treatment with SGLT2 inhibition
Canagliflozin roughly doubled lower-limb amputation, 6.3 vs 3.4 per 1,000 patient-years (CANVAS)
In the CANVAS program, canagliflozin was associated with about double the rate of lower-limb amputation compared with placebo (6.3 vs 3.4 per 1,000 patient-years; HR 1.97), mostly at the level of the toe or metatarsal. A later canagliflozin kidney trial did not reproduce the same size of amputation signal, so the risk is not fully settled, and it was studied in a high-risk diabetes population.Neal et al., canagliflozin and cardiovascular and renal events in type 2 diabetes (CANVAS Program)
Fournier gangrene, a perineal infection: 55 postmarketing cases across the class
A review of postmarketing reports identified 55 cases of Fournier gangrene, a necrotizing infection of the perineum, in people taking SGLT2 inhibitors over about six years, a rare but serious event seen across the drug class. These are spontaneous postmarketing reports, which cannot establish an incidence rate or prove the drug caused each case, but the signal was consistent enough to prompt a class warning.Bersoff-Matcha et al., Fournier gangrene associated with SGLT2 inhibitors: a review of spontaneous postmarketing cases
A prescription drug, and the decision sits with a clinician
These are prescription medicines. Whether one fits, and how it interacts with your kidney function, blood pressure and other medicines, is a decision made with a prescriber. This page gives no dose, because there is no safe general dose to give for a healthy person outside the diseases these drugs are approved to treat.
Ketoacidosis at near-normal blood sugar
These drugs can cause diabetic ketoacidosis, a dangerous buildup of acid in the blood, and they can do it while blood sugar reads close to normal, which makes it easy to miss. The risk rises around surgery, serious illness, dehydration, heavy alcohol use, and very low-carbohydrate eating. The standard guidance is to pause the drug during those situations, which is a plan a prescriber sets in advance.
Genital yeast and urinary infections
Because the drugs put sugar into the urine, they raise the rate of genital yeast infections in both men and women, most often early in treatment, and can contribute to urinary tract infections. These are usually treatable, and they are common enough to expect and plan for before starting.
Volume depletion and low blood pressure
The mild diuretic effect can tip into dehydration and low blood pressure, especially in older adults, in people already on other diuretics, and during illness with poor fluid intake. Staying well hydrated and reviewing other blood-pressure and fluid medicines with a prescriber is part of using these drugs safely.
Fournier gangrene, rare but serious
A rare but severe infection of the tissue around the genitals and perineum, called Fournier gangrene, has been reported across this drug class in postmarketing surveillance. Severe pain, swelling, redness or fever in that area, especially with feeling unwell, is a reason to seek care urgently.
The amputation signal with canagliflozin
In the CANVAS trial, canagliflozin was linked to about twice the rate of lower-limb amputation, mostly of toes and the mid-foot. Later trials of the same drug did not show the same size of effect, so the picture is not fully settled, and it is a specific reason to raise foot care and any existing foot problems with a prescriber.
Not a do-it-yourself longevity drug
There is no completed human trial that establishes a benefit or a dose for these drugs as a way to slow aging in a healthy person. The lifespan result is from male mice. If the longevity question interests you, the appropriate step is a conversation with a knowledgeable clinician who can weigh the trade-offs, not a purchase and a self-made protocol.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
When to See Someone
Most people who take these drugs for the right reason do well. Two situations on this short list are emergencies because they can look milder than they are. If either fits, get seen without waiting.
- Nausea, vomiting, abdominal pain, deep or rapid breathing, unusual drowsiness or confusion, even when a home glucose reading looks normal or near normal, which can be diabetic ketoacidosis and needs urgent assessment, because the normal-looking blood sugar is exactly what makes it easy to miss(seek urgent care)
- Severe pain, swelling, redness or tenderness of the genitals or the area between the genitals and the anus, especially with fever or feeling very unwell, which can be a fast-spreading infection called Fournier gangrene and needs emergency care(seek urgent care)
None of this is meant to alarm you. These drugs have a strong record in heart and kidney disease, and the reason these two signs are called out is that both are treatable when caught early and dangerous when missed. Any change to a prescribed medicine is a conversation with the person who prescribes it.
Common Questions
What do SGLT2 inhibitors actually do?
They block the kidney's reabsorption of glucose, so glucose leaves in the urine instead of returning to the blood. Normally the kidney reabsorbs almost all the glucose it filters through a transporter called SGLT2, and these drugs block it, so roughly 50 to 80 grams of glucose leave in the urine each day. That lowers blood sugar modestly and produces small drops in weight and blood pressure. The larger reason they are prescribed is protection of the heart and kidneys, which is bigger than the blood sugar change alone would predict.
Do they help people who do not have diabetes?
Yes, for two conditions. In DAPA-HF, dapagliflozin cut worsening heart failure or cardiovascular death in people with a weak heart, and in DAPA-CKD it slowed chronic kidney disease, and in both the benefit held whether or not the person had diabetes. That is why cardiologists and kidney specialists prescribe them beyond diabetes care. The benefit is established in people who have heart or kidney disease; it has not been tested in an otherwise healthy person.
Do SGLT2 inhibitors extend lifespan?
In people, that is not known. The evidence for lifespan is one animal result: in the Interventions Testing Program, canagliflozin extended median lifespan in male mice by about 14% and did nothing measurable in females. The proposed reasons, the daily loss of glucose calories and a shift toward ketones, are plausible, but no completed human trial tests any of these drugs for slowing aging. The established human benefit is protection of the heart and kidney in people who already have disease.
What are the main risks?
The one people miss most easily is ketoacidosis that can begin while blood sugar reads near normal, which is why the drugs are paused around illness and surgery. Genital yeast infections are common early on because of the sugar in the urine. The drugs act as a mild diuretic, so volume depletion and low blood pressure are a concern, especially in older adults and alongside other diuretics. Rare but serious is Fournier gangrene, an infection of the tissue around the perineum, and canagliflozin carried an amputation signal in one large trial.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 13 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.